151
Participants
Start Date
September 30, 2007
Primary Completion Date
December 31, 2009
Study Completion Date
May 31, 2011
SGN-40
2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
placebo
Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
rituximab
375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
etoposide
100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
carboplatin
AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
ifosfamide
5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
St. Vincent's Hospital - Sydney, Darlinghurst
Royal North Shore Hospital, St Leonards
Gosford & Wyong Hospital, Gosford
AZ Sint-Augustinus, Wilrijk
St. Vincent's Hospital, Melbourne, Fitzroy
The Royal Brisbane and Women's Hospital, Herston
Cliniques Universitaires UCL de Mont-Goddine, Yvoir
Royal Perth Hospital, Perth
Universite de Gent, Ghent
St. Luke's Roosevelt Hospital Center, New York
Azienda Ospedaliera Universitaria San Martino, Genova
Christiana Care Health Systems, Newark
Georgetown University, Washington D.C.
Hospital Ramon y Cajal, Madrid
Medical University of South Carolina, Charleston
Winship Cancer Institute, Emory University, Atlanta
Hematologie CHU Purpan, Toulouse
MD Anderson Cancer Center, Orlando, Orlando
Hopitaux du Haut Leveque, Pessac
Sarah Cannon Research Institute, Nashville
University of Louisville - James Graham Brown Cancer Center, Louisville
KH Maria Hilf-Franziskushaus, Mönchengladbach
Ohio State University, Columbus
Hopital Hotel Dieu, Nantes
Cleveland Clinic Foundation, Cleveland
Hospital Universitario La Fe, Valencia
Sparrow Regional Cancer Center, Lansing
Azienda Ospedaliera Universitaria Careggi, Florence
Azienda Ospedaliera Universitaria Senese, Siena
Johannes-Gutenberg Universitat Mainz, Mainz
Park Nicollet Institute, Saint Louis Park
Mayo Clinic Rochester, Rochester
Northwestern University, Chicago
Washington University School of Medicine, St Louis
Centre Leon Berard - Centre regional de lutte contre le cancer Rhone-Alpes, Lyon
Centre Hospitalier Lyon Sud, Pierre-Bénite
Baylor Sammons Cancer Center, Dallas
Groupe Hospitalier Necker - Enfants Malades, Paris
Centre Henri Becquerel, Rouen
Centre Hospitalier Andre Mignot, Le Chesnay
San Juan Oncology Associates, Farmington
Universitatsklinikum Ulm, Ulm
University of California at Los Angeles, Los Angeles
Institut Gustave-Roussy, Villejuif
Providence Portland Medical Center, Portland
MultiCare Health System, Tacoma
University of Alabama at Birmingham, Birmingham
Stanford University Medical Center, Stanford
University of Texas MD Anderson Cancer Center, Houston
West Virginia University, Morgantown
Fakultni nemocnice Hradec Kralove, Hradec Králové
Vseobecna fakultni nemocnice v Praze, Prague
Fakultni nemocnice v Motole, Prague
Debreceni Egyetem Orvos - es Egeszsegtudomanyi Centrum, Debrecen
Petz Aladar Megyei Oktato Korhaz, IInd Department of Internal Medicine, Győr
Kaposi Mor Oktato Korhaz, Kaposvár
H. Duran y Reynals Institue Catala D'Oncologia, Barcelona
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikat Kozpont, Szeged
Szpital Akademii Medycznej w Gdansku, Gdansk
Szpital Uniwersytecki w Krakowie, Krakow
Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz
Instytut Hematologii i Transfuzjologii, Warsaw
Centrum Onkologii Institut im. Marii Sklodowskiej-Curie, Warsaw
Samodzielny Publiczny Szpital Kliniczny Nr 1, Wroclaw
Hospital Clinic i Provincial, Barcelona
Hospital de la Santa Creu i Sant Paul, Barcelona
Collaborators (1)
Genentech, Inc.
INDUSTRY
Seagen Inc.
INDUSTRY